You just read:

Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

News provided by

Novartis

Dec 10, 2017, 10:47 ET